Rui Su Lab
Three overarching questions drive the Rui Su lab research program:
- How do RNA modifications and RBPs coordinate gene expression at the post-transcriptional level?
- Whether the dysregulation of RNA modifications or RBPs is associated with tumorigenesis?
- Can we develop novel therapeutic approaches targeting RNA modifications or RBPs to treat tumors?
Dr. Su's prior studies have determined the oncogenic role of FTO in AML as a demethylase of N6-methyladenosine (m6A, the most abundant modification in mRNA) (Cancer Cell, 2017). In addition, she discovered that FTO could act as a druggable target for leukemia therapy (Cell, 2018) and developed selective and effective novel small-molecule inhibitors targeting FTO to treat leukemia via attenuating leukemia stem cell self-renewal, reprogramming leukemia metabolism, and potentiating immunotherapy (Cancer Cell, 2019 & 2020; Molecular Cell, 2021). More recently, Dr. Su currently leads another study to reveal the robust oncogenic role and methyltransferase-independent mechanism of METTL16 in HCC (Nature Cell Biology, 2022).
Several foundation awards fund Dr. Su’s research program, including The Margaret E. Early Medical Research Trust, the Leukemia Research Foundation, and the American Association for the Study of Liver Disease Foundation. She also contributes to several NIH R01 grants as a co-investigator.
An assistant professor in the Department of Systems Biology, Rui Su, Ph.D., conducts research on RNA modification(s) and RNA-binding proteins (RBPs)-mediated post-transcriptional gene regulation in tumorigenesis.
- RNA-binding proteins and RNA granules in leukemogenesis
- Targeting RNA modification for leukemia therapy
- Mitochondrial RNA-binding proteins in tumorigenesis
- RNA-binding proteins in regulating mRNA translation and tumor metabolism
We collaborate with organizations in progressing the development of new treatments in our specialized areas of research.
Li Z*, Weng H*, Su R*, Weng X*, Zuo Z*, Li C, Huang H, Nachtergaele S, Dong L, Hu C, Qin X, Tang L, Wang Y, Hong GM, Huang H, Wang X, Chen P, Gurbuxani S, Arnovitz S, Li Y, Li S, Strong J, Neilly MB, Larson RA, Jiang X, Zhang P, Jin J, He C, Chen J. Cancer Cell. 2017 Jan 9;31(1):127-141. PMCID: PMC5234852. **Cover Story of this issue of Cancer Cell ***Highlighted (Research Watch) by Cancer Discovery (2017 Feb;7(2): OF9)
Su R*, Dong L*, Li C*, Nachtergaele S*, Wunderlich M, Qing Y, Deng X, Wang Y, Weng X, Hu C, Yu M, Skibbe J, Dai Q, Zou D, Wu T, Yu K, Weng H, Huang H, Ferchen K, Qin X, Zhang B, Qi J, Sasaki AT, Plas D, Bradner JE, Wei M, Marcucci G, Jiang X, Mulloy J, Jin J, He C, Chen J. Cell. 2018 Jan 11;172(1-2):90-105. ** Highlighted (Research Highlights) by Nature Reviews Cancer (2018 Jan 25;18(2):66.); ***Highlighted (Research Watch) by Cancer Discovery (2018 Feb;8(2):137).
Weng H, Huang H, Wu H, Qin X, Zhao BS, Dong L, Shi H, Skibbe J, Shen C, Hu C, Sheng Y, Wang Y, Wunderlich M, Zhang B, Dore L, Su R, Deng X, Ferchen K, Li C, Sun M, Lu Z, Jiang X, Marcucci G, Mulloy J, Yang J, Qian, Z, Wei M, He C, Chen J. Cell Stem Cell. 2018 Feb 1;22(2):191-205.
Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, Zhao BS, Mesquita A, Liu C, Yuan CL, Hu YC, Hüttelmaier S, Skibbe J, Su R, Deng X, Dong L, Sun M, Li C, Nachtergaele S, Wang Y, Hu C, Ferchen K, Greis KD, Jiang X, Wei M, Qu L, Guan JL, He C, Yang J, Chen J. Nature Cell Biology. 2018 Mar;20(3):285-295.
Huang H, Weng H, Zhou K, Wu T, Zhao BS, Sun M, Chen Z, Deng X, Xiao G, Auer F, Klemm L, Wu H, Zuo Z, Qin X, Dong Y, Zhou Y, Qin H, Tao S, Du J, Liu J, Lu Z, Yin H, Mesquita A, Yuan CL, Hu YC, Sun W, Su R, Dong L, Shen C, Li C, Qing Y, Jiang X, Wu X, Sun M, Guan JL, Qu LH, Wei M, Müschen M, Huang G, He C, Yang JH, Chen J. Nature. 2019 Mar 21;567(7748):414-419.
Duarte, CA 91010